Navigation Links
Clinical trial to test safety of drug targeting leukemia cells
Date:9/3/2014

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

CLL is the most common form of blood cancer in adults, with more than 15,000 new cases diagnosed each year in the United States. The new antibody targets ROR1, a protein used by embryonic cells during early development that is also exploited by cancer cells to promote tumor growth and metastasis the spreading of cancer throughout the body that is responsible for 90 percent of all cancer-related deaths.

ROR1 is not expressed by normal adult cells, making it a specific marker of cancer cells in general and cancer stem cells in particular. Because ROR1 is a primary driver of tumor growth and metastasis, researchers believe it presents an excellent target for anti-cancer therapy.

Developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, who holds the Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues, the antibody is called cirmtuzumab (also known as UC-961). In previous animal studies, Kipps' team reported that ROR1 is singularly expressed on CLL and also on a variety of different cancers, including cancers of the breast, pancreas, colon, lung and ovary. In mouse models of CLL, ROR1 acts as an accelerant when combined with another oncogene to produce a faster-growing, more aggressive cancer.

Cirmtuzumab is based on a humanized anti-ROR1 monoclonal antibody that, in mouse studies, reduced levels of ROR1, impairing the growth and survival of CLL cells and making them more vulnerable to other anti-cancer drugs. Cirmtuzumab was developed under the auspices of the CIRM HALT leukemia grant awarded to Dennis Carson, MD, principal investigator, and Catriona Jamieson, MD, PhD, co-principal investigator to develop six distinct therapies against cancer stem cells. Kipps led one of the six projects to generate antibodies against ROR1, leading to the cirmtuzumab trial in patients with CLL.

"The primary goal of this phase I clinical trial is to evaluate whether cirmtuzumab is a safe and well-tolerated cancer stem cell-targeted agent in patients with CLL," said Jamieson, chief of the Division of Regenerative Medicine, associate professor of medicine, director of stem cell research at UC San Diego Moores Cancer Center, deputy director of the Sanford Stem Cell Clinical Center and the principal investigator of the cirmtuzumab clinical trial.

Michael Choi, MD, assistant clinical professor of medicine and co-principal investigator of the clinical trial, said,"The trial will involve 33 to 78 patients with relapsed or refractory CLL, who will receive an intravenous infusion every 14 days at Moores, followed by regular monitoring and clinic visits to assess efficacy and identify and manage any adverse effects. Initial treatment is planned for two months."

Kipps suggested that drugs like cirmtuzumab, if ultimately shown to be effective, could lead to a new type of anti-cancer therapy. "Every drug has limits. Usually anti-cancer drugs cannot cure cancer. Even after achieving a good response to anti-cancer drugs, the cancer can come back and spread to other parts of the body," he said.

"This is thought to be due to cancer stem cells, which are relatively resistant to our current anti-cancer drugs. Because cancer stem cells may require ROR1 for their growth, survival and movement through the body, targeting ROR1 could be a way to eradicate the seeds of the cancer that are responsible for metastasis or relapse after other forms of treatment.

"I see cirmtuzumab as perhaps also synergizing with other forms of treatment to provide for more effective anti-cancer therapies. It's the cocktail approach, similar to what's been shown to be effective in treating patients with HIV. Multiple drugs attack multiple targets of the cancer, each eliminating subsets of malignant cells. When combined with anti-ROR1 therapy, we might also block the recurrence of cancer after treatment."

Kipps noted that discoveries like ROR1 are causing scientists to think of cancer metastasis in a different way. "It's sort of like the tumor is replaying a song we last played during our earliest stages of embryonic development, when our cells 'metastasized' to different sites to create our various organs. By turning off ROR1, we might end that tune and get on with life without cancer."


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions
2. Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis
3. Transvenous lead extraction clinically successful in 98 percent of cases
4. Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students
5. Novant Health Recognized for Excellence in Clinical Care
6. FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data
7. TGen receives approval for patient enrollment in brain cancer clinical trial
8. American Telemedicine Association Issues Clinical Guidelines for Telepathology
9. Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference
10. New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma
11. veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... The Touchpoint Solution’s new neuroscience wearable, Buzzies, generated over $100K in sales online ... $25,000 on Kickstarter to bring to the market what people are calling ... inventor, says she feels like she stumbled upon a miracle that she wants other ...
(Date:12/6/2016)... ... ... Of the variety of ingredients in the food supply, few spark more ... beliefs that hot dogs include “everything but the oink,” today’s wieners are made from ... meat and poultry in a hot dog recipe can add flavor, keep hot dogs ...
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle and high schools ... apply for a 2016/2017 California Casualty Thomas R. Brown Athletics Grant. The application ... receive up to $3,000. , The grant is named after California Casualty ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... charity, is thrilled to formally announce its Not a Moment to Lose fundraising ... Lose will rally supporters dedicated to declaring victory over cancer. The campaign aims ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016  Nearly 30 million people in ... the epidemic of diabetes. 1 However, nearly 40% ... glucose levels (hyperglycemia) and significant glucose variability. 2 These ... including cardiovascular events. If left untreated, hyperglycemia can lead ... disease or blindness. 3 As part ...
(Date:12/6/2016)... 6, 2016   Sienna Biopharmaceuticals, Inc. ... and aesthetics company, today announced it has ... pharmaceutical company focused on developing first-in-class topical ... psoriasis, atopic dermatitis and pruritus (itch). Under ... make an undisclosed upfront payment in cash ...
(Date:12/6/2016)... 6, 2016  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... focused on the development of novel therapies for ... U.S. Food and Drug Administration (FDA) has granted ... of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a novel, ... selectively regulates the expression of genes believed to ...
Breaking Medicine Technology: